GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models

Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and accumulation of intracellular α-synuclein (ɑ-syn) aggregates known as Lewy bodies and Lewy neurites. Levels of polyunsaturated fatty acids (PUFAs) have previously b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacological research 2024-11, Vol.209, p.107432, Article 107432
Hauptverfasser:	Ha, Tae-Young, Kim, Jae-Bong, Kim, Yeji, Park, Sang Myun, Chang, Keun-A
Format:	Artikel
Sprache:	eng
Schlagworte:	6-OHDA Animals Cell Line, Tumor Disease Models, Animal Dopaminergic Neurons - drug effects Dopaminergic Neurons - metabolism Dopaminergic Neurons - pathology GPR40 Humans Inflammasomes - drug effects Inflammasomes - metabolism Inflammation Male Mice Mice, Inbred C57BL Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use NLR Family, Pyrin Domain-Containing 3 Protein - metabolism NLRP3 Oxidopamine Parkinson Disease - drug therapy Parkinson Disease - metabolism Parkinsonian Disorders - chemically induced Parkinsonian Disorders - drug therapy Parkinsonian Disorders - metabolism Parkinson’s disease Receptors, G-Protein-Coupled - agonists Receptors, G-Protein-Coupled - metabolism α-synuclein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!